Jyong Biotech Ltd. Ordinary Shares (MENS)

TW — Healthcare Sector
Peers:

Automate Your Wheel Strategy on MENS

With Tiblio's Option Bot, you can configure your own wheel strategy including MENS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

 

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
ALAB, ARM, AXINU, CAI, EGG, IPO, IPOS, JCAP, KGF, MENS, PACHU, SLDE
Published: June 22, 2025 by: Seeking Alpha
Sentiment: Positive

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.

Read More
image for news U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

About Jyong Biotech Ltd. Ordinary Shares (MENS)

  • IPO Date 2025-06-17
  • Website jyongbio.com
  • Industry Biotechnology
  • CEO Kuo Fu-Feng
  • Employees 31
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages